Comprehensive Dermatologic Drug Therapy（4）

著者名：Wolverton MD, Stephen E/Wu MD, Jashin J.

Elsevier（2019/12/14発売）

• 言語：ENG
• ISBN：9780323612111
• eISBN：9780323612128

Description

Designed with practical usability in mind, Comprehensive Dermatologic Drug Therapy, 4th Edition, helps you safely and effectively treat the skin disorders you're likely to see in your practice. Dr. Stephen E. Wolverton and new associate editor Dr. Jashin J. Wu lead a team of global experts to bring you concise, complete guidance on today's full spectrum of topical, intralesional, and systemic drugs. You'll prescribe with confidence thanks to expert coverage of which drugs to use, when to use them, and adverse effects to monitor.- Includes new drug interaction tables, drug risk profiles, and FDA guidelines, as well as two new appendices that summarize chapter questions and summarize highest-risk drug interactions.- Covers the best uses for new biologic therapeutics.- Contains new chapters covering medical decision-making principles, PDE-4 and JAK inhibitors, interleukin 17 inhibitors, interleukin 23 inhibitors, additional biologic therapeutics, and hedgehog pathway inhibitors.- Contains quick-access summaries of indications/contraindications, dosage guidelines, drug interactions, drug monitoring guidelines, adverse effects, and treatment protocols.- Features a highly detailed, disease-specific index, as well as purchase information for major drugs.- Helps you assess your knowledge and prepare for certification or recertification with about 800 review questions and answers throughout the book.- Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.

Table of Contents

Part I: Introduction1 Basic Principles of Pharmacology2 Principles for Maximizing the Safety of Dermatologic Drug Therapy3 Polymorphisms: Why Individual Drug Responses Vary4 Adherence to Drug Therapy5 Medical Decision MakingPart II: Important Drug Regulatory Issues6 The FDA Drug Approval Process7 Pharmacovigilance: Verifying that Drugs Remain Safe8 Drugs Taken Off the Market: Important Lessons LearnedPart III: Systemic Drugs for Infectious Diseases9 Systemic Antibacterial Agents10 Systemic Antifungal Agents11 Systemic Antiviral Agents12 Systemic Antiparasitic AgentsPart IV: Systemic Immunomodulatory Drugs13 Systemic Corticosteroids14 Methotrexate15 Azathioprine16 Mycophenolates17 Cyclosporine18 Phosphodiesterase-4 and Janus Kinase Inhibitors19 Cytotoxic Agents20 Dapsone21 Antimalarial Agents22 Systemic RetinoidsPart V: Drugs Used in Conjunction with UV or Visible Light23 Psoralen Plus Ultraviolet A Photochemotherapy and Other Phototherapy Modalities24 Extracorporeal Photochemotherapy (Photopheresis)25 Photodynamic TherapyPart VI: Biologic Therapeutics26 Tumor Necrosis Factor Inhibitors27 Interleukin 12/23 Inhibitors28 Interleukin 17 Inhibitors29 Interleukin 23 Inhibitors30 Rituximab31 Additional Biologic Therapeutics: Dupilumab, Omalizumab, OthersPart VII: Miscellaneous Systemic Drugs32 Antihistamines33 Vasoactive and Antiplatelet Agents34 Antiandrogens and Androgen Inhibitors35 Psychotropic Agents36 Intravenous Immunoglobulin Therapy37 Systemic Anticancer Agents: Dermatologic Indications and Adverse Events38 Hedgehog Pathway Inhibitors39 Drugs for the Skinternist40 Miscellaneous Systemic DrugsPart VIII: Topical Drugs for Infectious Diseases41 Topical Antibacterial Agents42 Topical Antifungal Agents43 Topical and Intralesional Antiviral Agents44 Topical Antiparasitic AgentsPart IX: Topical Immunomodulatory Drugs45 Topical Corticosteroids46 Topical Retinoids47 Topical and Intralesional Chemotherapeutic Agents48 Topical Calcineurin Inhibitors49 Topical Vitamin D3Part X: Miscellaneous Topical Drugs50 Sunscreens51 Therapeutic Shampoos52 α-Hydroxy Acids53 Chemical Peels54 Products for the Care of Chronic Wounds55 Agents Used for Treatment of Hyperkeratosis56 Irritants and Allergens: When to Suspect Topical Therapeutic Agents57 Miscellaneous Topical AgentsPart XI: Injectable and Mucosal Routes of Drug Administration58 Local Anesthetics59 Injectable Dermal and Subcutaneous Fillers60 Botulinum Toxin Injections61 Oral Mucosal TherapeuticsPart XII: Major Adverse Effects From Systemic Drugs62 Hepatotoxicity of Dermatologic Drug Therapy63 Hematologic Toxicity of Drug Therapy64 Drug-induced Malignancy65 Dermatologic Drugs During Pregnancy and Lactation66 Drug Interactions67 Cutaneous Drug Reactions With Systemic FeaturesPart XIII: Special Pharmacology and Therapeutics Topics68 Informed Consent and Risk Management69 Compounding in Dermatology70 Dermatologic Drug Therapy in ChildrenAppendix I Core Questions for Understanding Systemic Dermatologic DrugsAppendix II The Most Potentially Serious Drug Interactions